NTLA — Intellia Therapeutics, Inc. Stock Price, Chart & AI Report

Negative Feb 7, 2026 • 14:05 UTC The Motley Fool • Prosper Junior Bakiny

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

Intellia Therapeutics (NTLA), a gene-editing biotech backed by Cathie Wood's Ark Invest, has surged 41% this year following FDA approval to lift a clinical hold on one of its phase 3 studies for nex-z. While the company targets large addressable markets in rare diseases with potential peak sales in the billions, significant clinical and regulatory risks remain. The stock is considered very risky due to challenges in gene editing medicine adoption and potential regulatory setbacks.

NTLA gene editing biotech clinical hold FDA approval rare diseases transthyretin amyloidosis hereditary angioedema

Sentiment note

Despite the 41% year-to-date gain and recent positive FDA development, the article concludes the stock remains 'very risky' for most investors. Key concerns include: ongoing clinical hold on second phase 3 study, historical regulatory setbacks (patient death from liver damage), challenges in gene editing medicine adoption despite high costs, and limited peak sales potential. The author recommends investors 'stay away' except those comfortable with heightened risk.

Positive Jan 22, 2026 • 09:56 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends

The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.

CRSP EDIT SGMO NTLA genome editing CRISPR gene therapy artificial intelligence

Sentiment note

Listed as key player in genome editing market experiencing substantial growth; benefits from AI integration reducing off-target effects and expanding clinical pipeline

Neutral Nov 4, 2025 • 08:35 UTC GlobeNewswire Inc. • Nova One Advisor

Gene Editing Market Size to Surpass USD 42.13 Billion by 2034

The global gene editing market is projected to grow from $11.29 billion in 2025 to $42.13 billion by 2034, with a CAGR of 15.76%. North America dominates the market, while CRISPR-Cas9 technology leads in market share. Key drivers include potential medical and agricultural applications.

NTLA TMO LLY A gene editing CRISPR biotechnology market growth

Sentiment note

Experienced a clinical hold on late-stage trials and temporarily paused patient dosing, indicating ongoing challenges in gene therapy development

Negative Nov 2, 2025 • 14:25 UTC The Motley Fool • Prosper Junior Bakiny

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

Intellia Therapeutics, a biotech company developing gene-editing therapies for rare diseases, faces significant risks after pausing clinical trials due to a patient experiencing liver damage. Despite potential blockbuster drug candidates, the stock's future remains uncertain.

NTLA REGN biotech gene-editing CRISPR clinical trials rare diseases

Sentiment note

The company experienced a major clinical trial setback with nex-z, which was paused due to a patient suffering liver damage. While the drugs have potential billion-dollar market opportunities, the safety concerns and high risk of failure in clinical-stage biotech make the outlook uncertain.

Positive Oct 2, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

CRISPR Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight

CRISPR therapies are showing significant potential with over 25 key companies developing 30+ pipeline therapies targeting genetic disorders, with promising clinical trials across various disease areas.

NTLA CRBU LLY CRISPR gene editing clinical trials genetic disorders biotechnology

Sentiment note

Completed Phase III enrollment for hereditary angioedema treatment and reported three-year follow-up data, demonstrating consistent progress in clinical development

Positive Sep 25, 2025 • 13:52 UTC Benzinga • Globe Newswire

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics reported positive Phase 1 trial results for its gene editing therapy nex-z, showing sustained transthyretin protein reductions and potential clinical improvements in patients with hereditary ATTR amyloidosis. The company expects to complete Phase 3 trial enrollment in 2026 and potentially file for biologics license by 2028.

NTLA REGN gene editing CRISPR ATTR amyloidosis clinical trial biotechnology

Sentiment note

Demonstrated long-term efficacy of experimental therapy, sustained protein reduction, potential clinical improvements, advancing to Phase 3 trials, and positive outlook for future regulatory submission

Positive Sep 18, 2025 • 19:08 UTC Benzinga • Piero Cingari

Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback

The Russell 2000 index reached an all-time high after the Federal Reserve signaled potential interest rate cuts, boosting small-cap stocks and providing cheaper borrowing opportunities for smaller companies.

ETNB BFLY BFLY.WS QSI small-cap Federal Reserve interest rates stock market

Sentiment note

Rallied 23.8% from renewed excitement in gene therapy

Positive Sep 18, 2025 • 18:33 UTC Benzinga • Evette Mitkov

Intellia Therapeutics Shares Are Ripping Higher: Here's Why

Intellia Therapeutics completed enrollment in its Phase 3 HAELO trial for lonvoguran ziclumeran within nine months, with topline data expected in the first half of 2026 and a potential U.S. launch planned for the first half of 2027.

NTLA Phase 3 trial HAELO hereditary angioedema biologics license application clinical development

Sentiment note

Stock price surged 24.28% due to successful trial enrollment, strong development timeline, and potential market launch of a new therapy for hereditary angioedema

Positive Sep 2, 2025 • 10:00 UTC GlobeNewswire Inc. • Sns Insider

Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider

The global gene editing market is projected to grow from USD 6.09 billion in 2024 to USD 15.46 billion by 2032, driven by CRISPR technology advances, therapeutic applications, and significant research funding, with North America leading market development.

CRSP EDIT NTLA TMO gene editing CRISPR biotechnology precision medicine

Sentiment note

Entered strategic collaboration to develop gene-editing therapies for autoimmune conditions, demonstrating expanding research scope

Negative Jul 31, 2025 • 23:13 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against Intellia Therapeutics following a class action complaint alleging breach of fiduciary duties related to the discontinuation of NTLA-3001 research and a 27% workforce reduction.

NTLA investigation class action fiduciary duties workforce reduction pharmaceutical research

Sentiment note

Company halted NTLA-3001 research, reduced workforce by 27%, experienced stock price drop from $12.02 to $10.20, and is facing potential legal action for allegedly misleading investors about research timeline and program viability

Positive Jun 15, 2025 • 14:45 UTC GlobeNewswire Inc. • N/A

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics announced positive three-year data from a Phase 1 trial of its gene editing therapy lonvo-z for hereditary angioedema (HAE). The data showed a 98% mean reduction in monthly HAE attack rate and all 10 patients were attack-free and treatment-free for a median of 23 months.

NTLA Intellia Therapeutics lonvo-z hereditary angioedema gene editing

Sentiment note

The article reports positive three-year data from Intellia's Phase 1 trial of its gene editing therapy lonvo-z for hereditary angioedema, showing significant reductions in attack rate and patients being attack-free and treatment-free for an extended period.

Positive May 23, 2025 • 13:29 UTC Investing.com • Marketbeat.Com

Analysts Think These Stocks Could More Than Double in Value

Analysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.

SEPN NTLA NVAX stocks healthcare biotechnology drug development growth potential

Sentiment note

Intellia is developing promising therapies for rare diseases and has a strong cash position to fund operations through early 2027. Analysts have a consensus price target of $36.90, roughly quadrupling the stock's current price.